“Adalimumab Efficacy in Hidradenitis Suppurativa Patients Is Sustained at Least Three Years With Weekly Dosing: Results from a Phase 3 Open-Label Extension Study (PIONEER)”. SKIN The Journal of Cutaneous Medicine 1, no. 3.1 (October 27, 2017): s128. Accessed April 10, 2025. https://skin.dermsquared.com/skin/article/view/81.